Top

Strahlentherapie und Onkologie

Published in:

Open Access 01-01-2014 | Original article

Definition of stereotactic body radiotherapy

Principles and practice for the treatment of stage I non-small cell lung cancer

Authors: Prof. Dr. M. Guckenberger, MD, N. Andratschke, H. Alheit, R. Holy, C. Moustakis, U. Nestle, O. Sauer

Published in: Strahlentherapie und Onkologie | Issue 1/2014

Abstract

This report from the Stereotactic Radiotherapy Working Group of the German Society of Radiation Oncology (Deutschen Gesellschaft für Radioonkologie, DEGRO) provides a definition of stereotactic body radiotherapy (SBRT) that agrees with that of other international societies. SBRT is defined as a method of external beam radiotherapy (EBRT) that accurately delivers a high irradiation dose to an extracranial target in one or few treatment fractions. Detailed recommendations concerning the principles and practice of SBRT for early stage non-small cell lung cancer (NSCLC) are given. These cover the entire treatment process; from patient selection, staging, treatment planning and delivery to follow-up. SBRT was identified as the method of choice when compared to best supportive care (BSC), conventionally fractionated radiotherapy and radiofrequency ablation. Based on current evidence, SBRT appears to be on a par with sublobar resection and is an effective treatment option in operable patients who refuse lobectomy.

Lax I, Blomgren H, Naslund I, Svanstrom R (1994) Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 33(6):677–683PubMedCrossRef

Uematsu M, Shioda A, Tahara K et al (1998) Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer 82(6):1062–1070PubMedCrossRef

Wulf J, Hadinger U, Oppitz U et al (2000) Stereotactic radiotherapy of extracranial targets: CT-simulation and accuracy of treatment in the stereotactic body frame. Radiother Oncol 57(2):225–236PubMedCrossRef

Herfarth KK, Debus J, Lohr F et al (2000) Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases. Int J Radiat Oncol Biol Phys 46(2):329–335PubMedCrossRef

Benedict SH, Yenice KM, Followill D et al (2010) Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 37(8):4078–4101PubMedCrossRef

Potters L, Kavanagh B, Galvin JM et al (2010) American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 76(2):326–332PubMedCrossRef

Kirkbride P, Cooper T (2011) Stereotactic body radiotherapy. Guidelines for commissioners, providers and clinicians: a national report. Clin Oncol 23(3):163–164CrossRef

Sahgal A, Roberge D, Schellenberg D et al (2012) The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy. Clin Oncol 24(9):629–639CrossRef

Loo BW, Chang JY, Dawson LA et al (2011) Stereotactic ablative radiotherapy: what’s in a name? Pract Radiat Oncol 1(1):38–39CrossRef

10.

Raz DJ, Zell JA, Ou SH et al (2007) Natural history of stage I non-small cell lung cancer: implications for early detection. Chest 132(1):193–199PubMedCrossRef

11.

Haasbeek CJ, Palma D, Visser O et al (2012) Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol 23(10):2743–2747PubMedCrossRef

12.

Palma D, Visser O, Lagerwaard FJ et al (2010) Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 28(35):5153–5159PubMedCrossRef

13.

Rowell NP, Williams CJ (2001) Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable). Cochrane Database Syst Rev 2:CD002935PubMed

14.

Sibley GS, Jamieson TA, Marks LB et al (1998) Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys 40(1):149–154PubMedCrossRef

15.

Martel MK, Ten Haken RK, Hazuka MB et al (1999) Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 24(1):31–37PubMedCrossRef

16.

Willner J, Baier K, Caragiani E et al (2002) Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 52(2):382–389PubMedCrossRef

17.

Partridge M, Ramos M, Sardaro A, Brada M (2011) Dose escalation for non-small cell lung cancer: analysis and modelling of published literature. Radiother Oncol 99(1):6–11PubMedCrossRef

18.

Ginsberg RJ, Rubinstein LV (1995) Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60(3):615–622 (discussion 622–613)PubMedCrossRef

19.

Shirvani SM, Jiang J, Chang JY et al (2012) Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 84(5):1060–1070PubMedCentralPubMedCrossRef

20.

Palma D, Lagerwaard F, Rodrigues G et al (2011) Curative treatment of stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys (Epub(Epub))

21.

Guckenberger M, Kestin LL, Hope AJ et al (2012) Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer? J Thorac Oncol 7(3):542–551PubMedCrossRef

22.

Nagata Y, Takayama K, Matsuo Y et al (2005) Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 63(5):1427–1431PubMedCrossRef

23.

Baumann P, Nyman J, Hoyer M et al (2009) Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 27(20):3290–3296PubMedCrossRef

24.

Fakiris AJ, McGarry RC, Yiannoutsos CT et al (2009) Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75(3):677–682PubMedCrossRef

25.

Ricardi U, Filippi AR, Guarneri A et al (2010) Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer 68(1):72–77PubMedCrossRef

26.

Timmerman R, Paulus R, Galvin J et al (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303(11):1070–1076PubMedCentralPubMedCrossRef

27.

Bral S, Gevaert T, Linthout N et al (2011) Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial. Int J Radiat Oncol Biol Phys 80(5):1343–1349PubMedCrossRef

28.

Grutters JP, Kessels AG, Pijls-Johannesma M et al (2010) Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol 95(1):32–40PubMedCrossRef

29.

Kopek N, Paludan M, Petersen J et al (2009) Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer. Radiother Oncol 93(3):402–407PubMedCrossRef

30.

NCCN Clinical Practice Guidelines in Oncology: Non-small cell lung cancer Version 1.2013 [http://www.nccn.org/]

31.

Renaud S, Falcoz PE, Olland A, Massard G (2013) Is radiofrequency ablation or stereotactic ablative radiotherapy the best treatment for radically treatable primary lung cancer unfit for surgery? Interact Cardiovasc Thorac Surg 16(1):68–73PubMedCrossRef

32.

Crabtree T, Puri V, Timmerman R et al (2013) Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). J Thorac Cardiovasc Surg 145(3):692–699PubMedCrossRef

33.

Grills IS, Mangona VS, Welsh R et al (2010) Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 28(6):928–935PubMedCrossRef

34.

Oshiro Y, Aruga T, Tsuboi K et al (2010) Stereotactic body radiotherapy for lung tumors at the pulmonary hilum. Strahlenther Onkol 186(5):274–279PubMedCrossRef

35.

Lagerwaard FJ, Verstegen NE, Haasbeek CJ et al (2012) Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 83(1):348–353PubMedCrossRef

36.

Senan S, Verstegen NE, Palma D et al (2012) Stages I–II non-small cell lung cancer treated using either lobectomy by video-assisted thoracoscopic surgery (VATS) or stereotactic ablative radiotherapy (SABR): outcomes of a propensity score-matched analysis. ASCO Meeting Abstracts 30(15_suppl):7009

37.

Shelkey J, Fakiris A, DeCamp MM et al (2012) Matched-pair comparison of outcome of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery. ASCO Meeting Abstracts 30(15_suppl):7040

38.

Bolliger CT, Wyser C, Roser H et al (1995) Lung scanning and exercise testing for the prediction of postoperative performance in lung resection candidates at increased risk for complications. Chest 108(2):341–348PubMedCrossRef

39.

Perrot M de, Licker M, Reymond MA et al (1999) Influence of age on operative mortality and long-term survival after lung resection for bronchogenic carcinoma. Eur Respir J 14(2):419–422PubMedCrossRef

40.

Swensen SJ, Silverstein MD, Ilstrup DM et al (1997) The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med 157(8):849–855PubMedCrossRef

41.

Herder GJ, Kramer H, Hoekstra OS et al (2006) Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 24(12):1800–1806PubMedCrossRef

42.

Patel VK, Naik SK, Naidich DP et al (2013) A practical algorithmic approach to the diagnosis and management of solitary pulmonary nodules: part 2: pretest probability and algorithm. Chest 143(3):840–846PubMedCrossRef

43.

Patel VK, Naik SK, Naidich DP et al (2013) A practical algorithmic approach to the diagnosis and management of solitary pulmonary nodules: part 1: radiologic characteristics and imaging modalities. Chest 143(3):825–839PubMedCrossRef

44.

Verstegen NE, Lagerwaard FJ, Haasbeek CJ et al (2011) Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. Radiother Oncol 101(2):250–254PubMedCrossRef

45.

Sawada S, Yamashita MK, Eisaku N et al (2007) Evaluation of resected tumors that were not diagnosed histologically but were suspected of lung cancer preoperatively. J Thorac Oncol 2(8):S422–S422CrossRef

46.

Murai T, Shibamoto Y, Baba F et al (2010) Progression of non-small-cell lung cancer during the interval before stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys

47.

De Ruysscher D, Faivre-Finn C, Nestle U et al (2010) European organisation for research and treatment of cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol 28(36):5301–5310CrossRef

48.

Stiles BM, Servais EL, Lee PC et al (2009) Point: clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging. J Thorac Cardiovasc Surg 137(1):13–19PubMedCrossRef

49.

Park HK, Jeon K, Koh WJ et al (2010) Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT. Respirology 15(8):1179–1184PubMedCrossRef

50.

Wolthaus JW, Sonke JJ, Herk M van et al (2008) Comparison of different strategies to use four-dimensional computed tomography in treatment planning for lung cancer patients. Int J Radiat Oncol Biol Phys 70(4):1229–1238PubMedCrossRef

51.

Guckenberger M, Krieger T, Richter A et al (2009) Potential of image-guidance, gating and real-time tracking to improve accuracy in pulmonary stereotactic body radiotherapy. Radiother Oncol 91(3):288–295PubMedCrossRef

52.

Paddick I (2000) A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. J Neurosurg 93(Suppl 3):219–222PubMed

53.

Lagerwaard FJ, Haasbeek CJ, Smit EF et al (2008) Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70(3):685–692PubMedCrossRef

54.

Onishi H, Araki T, Shirato H et al (2004) Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101(7):1623–1631PubMedCrossRef

55.

Wulf J, Baier K, Mueller G, Flentje MP (2005) Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol 77(1):83–87PubMedCrossRef

56.

Guckenberger M, Wulf J, Mueller G et al (2009) Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 74(1):47–54PubMedCrossRef

57.

Grills IS, Hope AJ, Guckenberger M et al (2012) A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol 7(9):1382–1393PubMedCrossRef

58.

Onimaru R, Fujino M, Yamazaki K et al (2008) Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys 70(2):374–381PubMedCrossRef

59.

Zhang J, Yang F, Li B et al (2011) Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys 81(4):e305–e316PubMedCrossRef

60.

Guckenberger M, Allgauer M, Appold S. Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S et al (2013) Safety and efficacy of stereotactic body radiotherapy for stage I non-small-cell lung cancer in routine clinical practice. Patterns-of-care and outcome analysis. J Thorac Oncol 8(8):1050–1058PubMedCrossRef

61.

Haedinger U, Krieger T, Flentje M, Wulf J (2005) Influence of calculation model on dose distribution in stereotactic radiotherapy for pulmonary targets. Int J Radiat Oncol Biol Phys 61(1):239–249PubMedCrossRef

62.

Senthi S, Haasbeek CJ, Slotman BJ, Senan S (2013) Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol 106(3):276–282PubMedCrossRef

63.

Timmerman R, McGarry R, Yiannoutsos C et al (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24(30):4833–4839PubMedCrossRef

64.

Hurkmans CW, Cuijpers JP, Lagerwaard FJ et al (2009) Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat Oncol 4:1PubMedCentralPubMedCrossRef

65.

Wulf J, Hadinger U, Oppitz U et al (2003) Impact of target reproducibility on tumor dose in stereotactic radiotherapy of targets in the lung and liver. Radiother Oncol 66(2):141–150PubMedCrossRef

66.

Guckenberger M, Meyer J, Wilbert J et al (2006) Cone-beam CT based image-guidance for extracranial stereotactic radiotherapy of intrapulmonary tumors. Acta Oncol 45(7):897–906PubMedCrossRef

67.

Guckenberger M, Heilman K, Wulf J et al (2007) Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. Radiother Oncol 85(3):435–442PubMedCrossRef

68.

Takeda T, Takeda A, Kunieda E et al (2004) Radiation injury after hypofractionated stereotactic radiotherapy for peripheral small lung tumors: serial changes on CT. AJR Am J Roentgenol 182(5):1123–1128PubMedCrossRef

69.

Kimura T, Matsuura K, Murakami Y et al (2006) CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers? Int J Radiat Oncol Biol Phys 66(2):483–491PubMedCrossRef

70.

Dunlap NE, Yang W, McIntosh A et al (2012) Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 84(5):1071–1077PubMedCrossRef

71.

Huang K, Dahele M, Senan S et al (2012) Radiographic changes after lung stereotactic ablative radiotherapy (SABR)—can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol 102(3):335–342PubMedCrossRef

72.

Fuks Z, Kolesnick R (2005) Engaging the vascular component of the tumor response. Cancer cell 8(2):89–91PubMedCrossRef

73.

Lee Y, Auh SL, Wang Y et al (2009) Therapeutic effects of ablative radiation on local tumor require CD8+T cells: changing strategies for cancer treatment. Blood 114(3):589–595PubMedCentralPubMedCrossRef

74.

Kirkpatrick JP, Meyer JJ, Marks LB (2008) The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol 18(4):240–243PubMedCrossRef

75.

Brenner DJ (2008) The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol 18(4):234–239PubMedCentralPubMedCrossRef

76.

Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S (2011) Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol 6(12):2036-2043.PubMedCrossRef

77.

Dunlap NE, Cai J, Biedermann GB et al (2010) Chest wall volume receiving > 30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 76(3):796–801PubMedCrossRef

78.

Stephans KL, Djemil T, Tendulkar RD et al (2012) Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT). Int J Radiat Oncol Biol Phys 82(2):974–980PubMedCrossRef

Title: Definition of stereotactic body radiotherapy
Principles and practice for the treatment of stage I non-small cell lung cancer
Authors: Prof. Dr. M. Guckenberger, MD
N. Andratschke
H. Alheit
R. Holy
C. Moustakis
U. Nestle
O. Sauer
Publication date: 01-01-2014
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 1/2014
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0450-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Definition of stereotactic body radiotherapy

Principles and practice for the treatment of stage I non-small cell lung cancer

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

From heart to heart for breast cancer patients—cardiovascular toxicities in breast cancer radiotherapy

Abstracts der 30. ÖGRO Jahrestagung

Volumetric evaluation of an alternative bladder point in brachytherapy for locally advanced cervical cancer

Conformal breast irradiation with the arm of the affected side parallel to the body

Survival and prognostic factors in non-small cell lung cancer patients with spinal bone metastases

Brain metastasis from non-small cell lung cancer (NSCLC)